Ibrutinib paula (936563-96-1) - Gaosi oloa Tuuina atu
AASraw gaosia Cannabidiol (CBD) paʻu ma Hemp Taua Suauʻu tele!

Ibrutinib

fua faatatau: Category:

E poloka e le polouti paʻu le polotini e taʻu o le Bruton's tyrosine kinase (BTK), e ono fesoasoani e taofiofia ai sela o le kanesa. O se ituaiga o tyrosine kinase taofiofia. Faʻaigoaina foi Imbruvica.

Faamatalaga oloa

Tulaga Autu

Igoa oloa Efuefu efuefu
Numera CAS 936563-96-1
Faiga Faʻavae Molecular C25H24N6O2
Fua Faatatau o le Umi 440.5
Synonyms Paʻu IBRUTINIB (PCI-32765);

(R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo-[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-;PCI-32765 (Ibrutinib powder);

1[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1Hpyrazolo [3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one).

Faʻaaliga Paʻepaʻe i le paʻepaʻe papaʻe
Teuina ma Taulimaina Teu i le uluaʻi faʻailoga koneteina i le vevela o le potu ma i se nofoaga matutu.

 

Ibrutinib Powder Faʻamatalaga

O le Ibrutinib pauta o se ituaiga o vailaʻau na faʻaogaina naʻo ia poʻo isi vailaʻau e togafitia ai tagata matutua ma le lukimia masani o le lymphocytic, lymphocytic lymphoma laititi, poʻo le Waldenstrom macroglobulinemia (o se ituaiga o le-Hodgkin lymphoma). E faʻaogaina foʻi naʻo oe e togafitia ai tagata matutua ma le mantle cell lymphoma poʻo le liʻo o le liʻo oona ua maua se tasi togafitiga. O loʻo suʻesuʻeina foʻi ile togafitia o isi ituaiga kanesa. E poloka e le polouti paʻu le polotini e taʻu o le Bruton's tyrosine kinase (BTK), e ono fesoasoani e taofiofia ai sela o le kanesa. O se ituaiga o tyrosine kinase taofiofia. Faʻaigoaina foi Imbruvica.

 

Ibrutinib Powder Faʻavae o Gaioiga

O le Ibrutinib pauta o se mea malosi ma le mafai ona toe faʻafitia le Bruton's tyrosine kinase (BTK), o se vaega taua o le B-cell receptor (BCR) ma cytokine receptor ala. Faʻaauauina le faʻamalosia o le B-cell receptor signaling e taua mo le ola o le leaga B-sela; O le taofiofi a le BTK e iʻu ai i le faʻaititia o le leaga sela B ma faʻasaoina.

 

Ibrutinib Powder Application

Ua faʻamaonia le paʻu o le paʻu paʻia i Europa i Europa mo le togafitia o ituaiga e fitu o le lymphoma.

 

♦ Mantle sela lymphoma

Mo tagata o latou lymphoma ua toe paʻu (toe foʻi mai) pe leʻi tali atu i togafitiga (refactory lymphoma). Ibrutinib efuefu e avatua na o ia.

 

♦ Leukemia masani o le lymphocytic (CLL)

Mo tagata e leʻi iai ni togafitiga mo latou CLL (togafitiga muamua). E mafai ona tuʻuina atu ia Ibrutinib paula ia te ia lava pe tuʻufaʻatasi ma le rituximab poʻo le obinutuzumab (vailaʻau faʻamalosi tino). Mo tagata ua toe paʻu le latou CLL pe a maeʻa togafitiga. Mo tagata e toe faʻasolosolo CLL, ibrutinib paula e mafai ona tuʻuina atu ia te ia pe faʻatasi ma le bendamustine (o le chemotherapy drug) ma le rituximab.

 

♦ Waldenström's macroglobulinaemia (WM)

Mo tagata na muamua mauaina isi togafitiga mo WM. Mo tagata e le mafai ona maua le chemo-immunotherapy (chemotherapy ma le vailaau faʻamalositino) o togafitiga muamua.

O le faʻamaonia a Europa e faʻaaoga ai le ibrutinib paʻu i le CLL ma le mantle cell lymphoma na faʻatagaina ia Novema 2014. Na faʻasolo atu ia WM ia Me 2015. I le 2016, o le European Medicines Agency (EMA) na faʻalauteleina le faʻaaogaina o le pauta ibrutinib mo CLL.

Ibrutinib paula o loʻo faʻataʻitaʻia i isi falemaʻi faʻataʻitaʻiga i tagata ma nei ituaiga o lymphoma. Lenei e iloa ai pe a fai e mafai ona galue ibrutinib paula sili atu i le tuʻufaʻatasia ma isi togafitiga, e pei o chemotherapy poʻo vailaʻau togafitiga (mo se faʻataʻitaʻiga, rituximab). O loʻo faʻataʻitaʻia foʻi i isi ituaiga o lymphoma. Faʻaaoga la matou suʻesuʻega faʻamaumauga e iloa ai pe i ai se faʻataʻitaʻiga falemaʻi atonu e talafeagai mo oe i le Lymphoma TrialsLink.

 

Ibrutinib Powder Itu Aafiaga & Lapataiga

Maua se fesoasoani faafomaʻi faʻapitoa pe afai o iai lau faʻailoga o se faʻafitauli o le faʻalavelave; manava malosi; fulafula o ou foliga, laugutu, laulaufaiva, poo le faai.

Taofi le faʻaaogaina o le ibrutinib paʻu ma valaʻau lau fomaʻi i le taimi e tasi pe a fai oe i ai:

▪ faʻailoga o le faʻamaʻi –fiva, malulu, vaivai, papala gutu, tale ma papala, faʻafitauli manava;

▪ faʻailoga o le palapala i totonu o lou tino – niniva, vaivai, le mautonu, faʻafitauli i le tautala, umi le tiga o le ulu, paʻu uli poʻo le toto, o le piniki poʻo le enaena mimi, poʻo le tale o le toto poʻo le puaʻi e foliga mai o le kofe;

▪ ogaoga po o faaauau pea le manava tata;

▪ tiga o le fatafata, tatavale fatu tata pe o loʻe solo i lou fatafata, lagona e pei o oe o le a mou atu;

▪ tiga tiga o le ulu, pupula le vaai, tata lou ua po o taliga;

▪ faigofie ona gagase, e le masani ai le tafetotoi, lanu viole poʻo mumu mumu i lalo o lou paʻu;

▪ paʻe paʻe, malulu lima ma vae;

▪ faʻafitauli o fatugaʻo –e laitiiti pe leai foi se mimi, fulafula i ou vae poʻo tapuvae; pe

▪ faʻailoga o le sela sela ua malepe – le mautonu, vaivaiga, faʻamaʻi o maso, niniva, puaʻi, vave pe tuai le tata o le fatu, faʻaititia le urination, paʻu i ou lima ma vae poʻo tafatafa o lou gutu.

 

O aʻafiaga lautele masani e aofia ai:

▪ manava manava, niniva;

▪ fiva, tale, faafitauli i le manava;

▪ paʻu poʻo papala i lou gutu;

▪ lagona le lelava;

▪ mago, mageso; pe

▪ tiga o maso, tiga o ponaivi.

 

E leʻo se lisi atoa o aʻafiaga i itu ma isi e ono tupu. Valaau lau fomaʻi mo fautuaga faʻafomaʻi e uiga i aʻafiaga o le itu. E mafai ona e lipotia aʻafiaga i le FDA i 1-800-FDA-1088.

 

Tusitaiala

[1] Ahn IE, Jerussi T, Farooqui M, Tian X, Wiestner A, Gea-Banacloche J. Atypical Pneumocystis jirovecii niumonia i tagata mamaʻi na muamua togafitia ma CLL i luga o le tasi-sooupu ibrutinib paura. Toto. 2016; 128 (15): 1940-1943. [PubMed 27503501].

[2] Wang ML, Tulafono S, Martin P, et al. Faʻatulagaina le BTK ma le ibrutinib paʻu i le toe faʻafouina poʻo le faʻaaogaina o sela-sela lymphoma. N Engl J Med, 2013; 369 (6): 507-516. [PubMed 23782157].

[3] Byrd JC, Furman RR, Coutre SE, et al. O le faʻatulagaina ole BTK ma le pauta ibrutinib ile toe maua ai ole kanesa o le lymphocytic tumau. N Engl J Med. 2013; 369 (1): 32-42. [PubMed 23782158].

[4] Kamel S, Horton L, Ysebaert L, et al. E faʻaititia e Ibrutinib efuefu collagen-faʻafesoʻotaʻi ae le o le ADP-faʻatosinaina platelet faʻaputuputuina. Leukemia 2015; 29 (4): 783-787. [PubMed 25138588].

[5] Marostica E, Sukbuntherng J, Loury D, et al. Tagata faʻataʻitaʻi vailaʻau o le ibrutinib paʻu, o le Bruton tyrosine kinase inhibitor, i tagata mamaʻi ma sela sela B. Kanesa Chemother Pharmacol. 2015; 75 (1): 111-121. [PubMed 25381051].

[6] Salem JE, Manouchehri A, Bretagne M, et al. Laʻau oona e faʻafesoʻotaʻi ma le pauta ibrutinib. J Am Coll Cardiol. 2019; 74: 1667-1678. faia: 10.1016 / j.jacc.2019.07.056. [PubMed 31558250].

[7] Imbruvica (ibrutinib paʻu) [faʻamatalaina faʻamatalaga]. Sunnyvale, CA: Fale Talavai; Aperila 2020 ..

[8] Treon SP, Tripsas CK, Meid K et al. Ibrutinib paula i le taimi muamua na togafitia muamua Waldenström's macroglobulinemia. N Engl J Med. 2015; 372 (15): 1430-1440. [PubMed 25853747].